Share on StockTwits

Cambrex (NYSE:CBM) CEO Steven M. Klosk sold 4,702 shares of Cambrex stock on the open market in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $22.00, for a total value of $103,444.00. Following the completion of the transaction, the chief executive officer now directly owns 145,870 shares of the company’s stock, valued at approximately $3,209,140. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Cambrex (NYSE:CBM) traded up 0.79% on Thursday, hitting $21.70. The stock had a trading volume of 76,930 shares. Cambrex has a 1-year low of $12.56 and a 1-year high of $23.88. The stock’s 50-day moving average is $21.59 and its 200-day moving average is $20.59. The company has a market cap of $665.7 million and a P/E ratio of 20.20.

Cambrex (NYSE:CBM) last posted its quarterly earnings results on Tuesday, August 12th. The company reported $0.32 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.21 by $0.11. On average, analysts predict that Cambrex will post $1.08 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Cambrex from a “neutral” rating to an “outperform” rating in a research note on Monday, August 11th. They now have a $23.20 price target on the stock. Separately, analysts at First Analysis downgraded shares of Cambrex from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 8th. Finally, analysts at Longbow Research raised their price target on shares of Cambrex to $27.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock.

Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.

Receive News & Ratings for Cambrex Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co and related companies with Analyst Ratings Network's FREE daily email newsletter.